Co-use of a clusterin inhibitor with an EGFR inhibitor to treat cancer
Epidermal growth factor receptor (EGFR) expression and phosphorylation is increased in cancer cells treated with anti-clusterin antibodies. Such treatment is also accompanied with the reappearance of an epithelial phenotype of the cancer cell, as determined by an increased E-cadherin expression at the surface of cancer cells. Clusterin inhibitors may thus induce reversal of the epithelial to mesenchymal phenotype and restore sensitivity of cancer cells to EGFR inhibitors. Combinations of a clusterin inhibitor and an EGFR as well as their use in treatment of cancer are thus provided herewith.
1. A method of treating carcinoma comprising administering an anti-clusterin antibody or an antigen binding fragment thereof that binds to amino acids 421 to 443 of human clusterin and that is capable of inhibiting epithelial-to-mesenchymal transition (EMT) and an epidermal growth factor receptor (EGFR) inhibitor to an individual having or suspected of having breast carcinoma, prostate carcinoma, colorectal carcinoma, head and neck carcinoma, lung carcinoma, pancreatic cancer or renal cell carcinoma wherein the EGFR inhibitor is an EGFR tyrosine kinase inhibitor selected from the group consisting of gefitinib, erlotinib, imatinib, lapatinib or semazinib.
2. The method of claim 1 , wherein the anti-clusterin antibody or antigen binding fragment thereof and the EGFR inhibitor are administered sequentially.
3. The method of claim 1 , wherein the anti-clusterin antibody or antigen binding fragment thereof is administered prior to the EGFR inhibitor.
4. The method of claim 1 , wherein the anti-clusterin antibody or antigen binding fragment thereof is administered concurrently with the EGFR inhibitor.
5. The method of claim 1 , wherein the breast carcinoma is triple negative breast cancer or basal-like breast cancer.
6. The method of claim 1 , wherein the lung carcinoma is non-small cell lung cancer.
7. The method of claim 1 , wherein the anti-clusterin antibody or antigen binding fragment thereof comprises a CDRH1 as set forth in SEQ ID NO:1 or as set forth in SEQ ID NO:45, a CDRH2 as set forth in SEQ ID NO:2 or in SEQ ID NO:46 and a CDRH3 as set forth in SEQ ID NO:3 or in SEQ ID NO:47; and/or a CDRL1 as set forth in SEQ ID NO:4 or in SEQ ID NO:48, a CDRL2 as set forth in SEQ ID NO:5 or in SEQ ID NO:49, and a CDRL3 as set forth in SEQ ID NO:6.
8. The method of claim 1 , wherein the carcinoma comprises cells characterized by mesenchymal markers, by a loss of epithelial markers and/or by an epithelial-to-mesenchymal transition phenotype.
9. The method of claim 1 , wherein the anti-clusterin antibody or antigen binding fragment thereof comprises a heavy chain variable domain comprising the amino acid sequence set forth in SEQ ID NO:7 and a light chain variable domain comprising the amino acid sequence set forth in SEQ ID NO:8.
10. The method of claim 1 , wherein the anti-clusterin antibody or antigen binding fragment thereof comprises a heavy chain comprising the amino acid sequence set forth in SEQ ID NO:9 and a light chain comprising the amino acid sequence set forth in SEQ ID NO:10.
11. The method of claim 1 , wherein the anti-clusterin antibody or antigen binding fragment thereof is encoded by nucleic acids comprising the nucleotide sequence set forth in SEQ ID NO:22 and SEQ ID NO:23.
12. The method of claim 1 , wherein the carcinoma is metastatic.
13. A method for reducing the growth of carcinoma cells comprising administering an anti-clusterin antibody or an antigen binding fragment thereof that binds to amino acids 421 to 443 of human clusterin and that is capable of inhibiting epithelial-to-mesenchymal transition (EMT) and an epidermal growth factor receptor (EGFR) inhibitor to an individual having or suspected of having breast carcinoma, prostate carcinoma, colorectal carcinoma, head and neck carcinoma, lung carcinoma, pancreatic cancer or renal cell carcinoma wherein the EGFR inhibitor is an EGFR tyrosine kinase inhibitor selected from the group consisting of gefitinib, erlotinib, imatinib, lapatinib or semazinib.
14. The method of claim 13 , wherein the anti-clusterin antibody or antigen binding fragment thereof comprises:
a) a heavy chain variable domain comprising a CDRH1 as set forth in SEQ ID NO:1 or as set forth in SEQ ID NO:45, a CDRH2 as set forth in SEQ ID NO:2 or in SEQ ID NO:46 and a CDRH3 as set forth in SEQ ID NO:3 or in SEQ ID NO:47; and/or a light chain variable domain comprising a CDRL1 as set forth in SEQ ID NO:4 or in SEQ ID NO:48, a CDRL2 as set forth in SEQ ID NO:5 or in SEQ ID NO:49, and a CDRL3 as set forth in SEQ ID NO:6;
b) a heavy chain variable domain comprising the amino acid sequence set forth in SEQ ID NO:7 and a light chain variable domain comprising the amino acid sequence set forth in SEQ ID NO:8, or;
c) a heavy chain comprising the amino acid sequence set forth in SEQ ID NO:9 and a light chain comprising the amino acid sequence set forth in SEQ ID NO:10.
15. The method of claim 13 , wherein the anti-clusterin antibody or antigen binding fragment thereof and the EGFR inhibitor are administered sequentially or concurrently or wherein the anti-clusterin antibody or antigen binding fragment thereof is administered prior to the EGFR inhibitor.
16. The method of claim 13 , wherein the lung carcinoma is non-small cell lung cancer.
17. The method of claim 13 , wherein the carcinoma is metastatic.